Objective: The evidence between age at menarche and mortality risk is controversial. We aimed to quantify the dose-response association of age at menarche and risk of all-cause and cardiovascular disease (CVD) mortality based on cohort studies.
Methods: PubMed, EMBASE, Web of Science, and Scopus databases were searched up to March 15, 2018 for relevant articles. Random-effects models and restricted cubic splines were used for this meta-analysis.
Results: Twelve cohort studies, with 79,363 deaths and 2,341,769 participants, met the inclusion criteria. With each 1-year increase in menarche age, the relative risk (RR) was reduced for all-cause mortality (RR: 0.977, 95% confidence interval [CI]: 0.970-0.984), CVD mortality (RR: 0.993, 95% CI: 0.975-1.011), ischemic heart disease (IHD) mortality (RR: 0.969, 95% CI: 0.947-0.993), and stroke mortality (RR: 0.983, 95% CI: 0.954-1.012). We found a nonlinear dose-response association (Pnonlinearity = 0.001) between age at menarche and all-cause mortality, with the lowest risk observed at menarche age 15 years (RR: 0.849 95% CI: 0.800-0.901), but no evidence of a nonlinear association between menarche age and CVD mortality (Pnonlinearity = 0.543), IHD mortality (Pnonlinearity = 0.310), or stroke mortality (Pnonlinearity = 0.824).
Conclusions: Age at menarche is inversely associated with all-cause and IHD mortality.